

Capucine Baldini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2684165/publications.pdf>

Version: 2024-02-01

34
papers

948
citations

687363

13
h-index

454955

30
g-index

38
all docs

38
docs citations

38
times ranked

2007
citing authors

#	ARTICLE	IF	CITATIONS
1	Innovating Strategies and Tailored Approaches in Neuro-Oncology. <i>Cancers</i> , 2022, 14, 1124.	3.7	3
2	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs. <i>European Journal of Cancer</i> , 2022, 167, 42-53.	2.8	2
3	Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. <i>Cancers</i> , 2022, 14, 92.	3.7	3
4	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	4.2	12
5	Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2021, 39, 193-201.	2.6	10
6	Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600E Mutant Adult Glial and Glioneuronal Tumors. <i>Neurology</i> , 2021, 97, e673-e683.	1.1	16
7	Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B cell lymphoma: Results of LNH-EPI study. <i>American Journal of Hematology</i> , 2021, 96, E376-E379.	4.1	2
8	Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic. <i>Cancer Cell</i> , 2021, 39, 1039-1041.	16.8	2
9	Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. <i>Brain Communications</i> , 2021, 3, fcab220.	3.3	16
10	How Much Can We Bet on Activity of BET Inhibitors Beyond NUT Midline Carcinoma?. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz092.	2.9	7
11	Clinical consideration for choosing combination therapies in advanced non-small-cell lung cancer: age, Eastern Cooperative Organization performance status 2, steroids and Antibiotics. <i>Future Oncology</i> , 2020, 16, 1683-1690.	2.4	4
12	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	2.8	21
13	Surgical and regional treatments for colorectal cancer metastases in older patients: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0230914.	2.5	16
14	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	27.8	374
15	Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e67-e67.	0.9	40
16	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 389-397.	1.0	20
17	<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2505-2512.	2.0	17
18	PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 337-345.	1.0	25

#	ARTICLE	IF	CITATIONS
19	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	7.0	96
20	Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. <i>Investigational New Drugs</i> , 2018, 36, 62-74.	2.6	3
21	Are phase I trials safe for older patients?. <i>Journal of Geriatric Oncology</i> , 2018, 9, 87-92.	1.0	4
22	What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. <i>Journal of Oncology Practice</i> , 2018, 14, 85-94.	2.5	120
23	Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?. <i>British Journal of Cancer</i> , 2018, 119, 937-939.	6.4	7
24	Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 787-801.	4.1	15
25	Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers. <i>Oncotarget</i> , 2018, 9, 9741-9750.	1.8	12
26	Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials. <i>Blood</i> , 2018, 132, 2992-2992.	1.4	0
27	Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4110-4110.	1.4	0
28	Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations. <i>Cancer Treatment Reviews</i> , 2017, 57, 58-66.	7.7	54
29	Prognostic factors and outcome of patients with hematological malignancies in phase I trials. <i>Anti-Cancer Drugs</i> , 2017, 28, 540-545.	1.4	1
30	Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine. <i>In Vivo</i> , 2017, 31, 731-735.	1.3	6
31	Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma. <i>Case Reports in Oncology</i> , 2015, 8, 447-450.	0.7	12
32	VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2202-2211.	1.5	23
33	A Simple Scoring System for Identifying Relapsed/Refractory Lymphoma Patients Prematurely Withdrawn from Phase I Trials: The Gustave Roussy Experience. <i>Blood</i> , 2014, 124, 1759-1759.	1.4	0
34	Prognostic Factors and Outcome of Patients with Hematological Malignancies in Phase I Trials: The Gustave Roussy Scoring System. <i>Blood</i> , 2014, 124, 3504-3504.	1.4	0